LOGIN  |  REGISTER
Astria Therapeutics

Electromed to Participate in Upcoming Investor Conferences

February 26, 2025 | Last Trade: US$22.27 0.04 0.18

NEW PRAGUE, Minn. / Feb 26, 2025 / Business Wire / Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that management will participate in the following upcoming investor conferences:

The Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

  • Management will present at 10:30 a.m. Eastern Time on Tuesday, March 18, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations. Interested parties may also access the live webcast here. Investors may request meetings through their Oppenheimer representative.

The Sidoti Virtual Small-Cap Conference

  • Management will present at 1:45 p.m. Eastern Time on Thursday, March 20, 2025. A link to the live and archived webcast of the event will be available on the Electromed website under Events & Presentations.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page